[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592951":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":65,"collaborators":67,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":7,"studyType":84,"phases":7,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Anifrolumab","Anifrolumab prescribed per local practice",[14],"Saphnelo",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[22,35,45,55],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":7},"Research Site","RECRUITING","Copenhagen","23000","Denmark","DK",{"type":30,"coordinates":31},"Point",[32,33],12.56553,55.67594,{"lat":33,"lon":32},{"facility":23,"status":24,"city":36,"state":7,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":44,"contacts":7},"Charenton-le-Pont","94220","France","FR",{"type":30,"coordinates":41},[42,43],2.41217,48.82209,{"lat":43,"lon":42},{"facility":23,"status":24,"city":46,"state":7,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"Essen","45128","Germany","DE",{"type":30,"coordinates":51},[52,53],7.01228,51.45657,{"lat":53,"lon":52},{"facility":23,"status":24,"city":56,"state":7,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":7},"Barcelona","08007","Spain","ES",{"type":30,"coordinates":61},[62,63],2.15899,41.38879,{"lat":63,"lon":62},{"type":66,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[68],{"name":69,"class":6},"IQVIA Pty Ltd","100592951","anifrolumab-malignancy-and-serious-infections-study-100592951",false,"NCT07000110","Anifrolumab Malignancy and Serious Infections Study","A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab","SIMA","Inclusion Criteria:\n\n* First prescription of anifrolumab in the study period (no anifrolumab prescription prior to index date): date of first anifrolumab prescription will be the index date\n* A minimum data availability of 12 months prior to index date\n* Age ≥18 years at index date\n* SLE severity: patients with moderate to severe SLE at index date\n* SLE activity: patients with at least a flare (uncontrolled SLE) in the 6 months prior to index date\n\nExclusion Criteria:\n\n* A diagnosis of any malignancy prior to index date\n* A diagnosis of HIV\u002FAIDS or congenital immunodeficiency prior to index date\n* Organ or bone marrow transplant procedure prior to index date\n* A diagnosis of serious infection in the previous 6 months","ALL","18 Years","130 Years",{"count":82,"type":83},3195,"ESTIMATED","OBSERVATIONAL","This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate\u002Fsevere SLE patients who receive anifrolumab compared with a comparable population of moderate\u002Fsevere SLE patients on standard of care who do not initiate anifrolumab.",[87],"Systemic Lupus Erythematosus",[89],"malignancies, infections, anifrolumab","2026-06-18",{"date":92,"type":93},"2026-06-22","ACTUAL",{"date":95,"type":93},"2026-01-26",{"date":97,"type":83},"2031-11-30",{"name":5,"class":6},4]